Abstract
Background: Depression and anxiety are common neuropsychiatric complaints in patients with Systemic Lupus Erythematosus (SLE). While numerous studies have been performed to investigate the prevalence, impact, and associated factors of depression and anxiety, current literature presents mixed results. In particular, the prevalence of anxiety and depression varies substantially between studies due to methodological limitations, and heterogeneity in defining anxiety and depression, patient selection, and metrics used. Moreover, there is a lack of studies evaluating the validity, reliability, and interpretability of commonly used screening tools for depression and anxiety in SLE patients.
Result and Conclusion: Further investigations should aim to reach a consensus surrounding the role of controversial associated factors in depression and anxiety of SLE patients, while also focusing on the identification of novel factors that have not yet been highlighted in the literature.
Keywords: Systemic lupus erythematosus, patient-reported outcomes, anxiety, depression, factors, autoimmune disease.
[2]
Petri M, Naqibuddin M, Carson KA, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010; 37(10): 2032-8.
[3]
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42(4): 599-608.
[4]
Nikpour M, Bridge JA, Richter S. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: Identifying areas of unmet need. Intern Med J 2014; 44(12a): 1170-9.
[5]
Afeltra A, Garzia P, Mitterhofer AP, et al. Neuropsychiatric lupus syndromes: Relationship with antiphospholipid antibodies. Neurology 2003; 61(1): 108-10.
[6]
Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 695-700.
[7]
Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology 2002; 58(8): 1214-20.
[8]
Moustafa A, Eder L, Wither JE, et al. Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys.[abstract]. Arthritis Rheumatol 2016; 68.
[9]
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136-48.
[10]
Julian LJ, Gregorich SE, Tonner C, et al. Using the center for epidemiologic studies depression scale to screen for depression in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63(6): 884-90.
[11]
Julian LJ, Tonner C, Yelin E, et al. Cardiovascular and Disease Related Predictors of Depression in SLE. Arthritis Care Res (Hoboken) 2011; 63(4): 542-9.
[12]
Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009; 61(2): 240-6.
[13]
Greco CM, Li T, Sattar A, et al. Association between depression and vascular disease in systemic lupus erythematosus. J Rheumatol 2012; 39(2): 262-8.
[14]
Lisitsyna TA, Vel’tishchev DIu, Seravina OF, et al. Prevalence of mental disorders in SLE patients: correlations with the disease activity and comorbid chronic conditions. Ter Arkh 2009; 81(6): 10-6.
[15]
Xie LF, Chen PL, Pan HF, et al. Prevalence and correlates of suicidal ideation in SLE inpatients: Chinese experience. Rheumatol Int 2012; 32(9): 2707-14.
[16]
Zakeri Z, Shakiba M, Narouie B, Mladkova N, Ghasemi-Rad M, Khosravi A. Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience. Rheumatol Int 2012; 32(5): 1179-87.
[17]
Jönsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology (Oxford) 2002; 41(11): 1308-12.
[18]
Ward MM, Lotstein DS, Bush TM, Lambert RE, van Vollenhoven R, Neuwelt CM. Psychosocial correlates of morbidity in women with systemic lupus erythematosus. J Rheumatol 1999; 26(10): 2153-8.
[19]
Pettersson S, Lövgren M, Eriksson LE, et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012; 41(5): 383-90.
[20]
Mak A, Tang CS, Ho RC. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 2013; 22(3): 254-61.
[21]
Shen B, Feng G, Tang W, et al. The quality of life in Chinese patients with systemic lupus erythematosus is associated with disease activity and psychiatric disorders: A path analysis. Clin Exp Rheumatol 2014; 32(1): 101-7.
[22]
Fonseca R, Bernardes M, Terroso G, de Sousa M, Figueiredo-Braga M. Silent burdens in disease: Fatigue and depression in SLE. Autoimmune Dis 2014; 2014: 790724.
[23]
Maneeton B, Maneeton N, Louthrenoo W. Prevalence and predictors of depression in patients with systemic lupus erythematosus: A cross-sectional study. Neuropsychiatr Dis Treat 2013; 9: 799-804.
[24]
Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008; 59(12): 1788-95.
[25]
Sundquist K, Li X, Hemminki K, Sundquist J. Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases: A nationwide study from Sweden. Arch Gen Psychiatry 2008; 65(5): 501-7.
[26]
Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000; 9(8): 601-6.
[27]
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43(6): 521-30.
[28]
Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 2003; 25(11): 2958-71.
[29]
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17): 1836-41.
[30]
Mok CC, Chan KL, Ho LY. Association of depressive/anxiety symptoms with quality of life and work ability in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2016; 34(3): 389-95.
[31]
Hawro T, Krupińska-Kun M, Rabe-Jabłońska J, et al. Psychiatric disorders in patients with systemic lupus erythematosus: Association of anxiety disorder with shorter disease duration. Rheumatol Int 2011; 31(10): 1387-91.
[32]
Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61(8): 807-16.
[33]
Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992; 60(6): 835-44.
[34]
Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: Comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 1999; 60(7): 492-9.
[36]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[39]
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56(6): 893-7.
[40]
Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken) 2011; 63(Suppl. 11): S467-72.
[41]
Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. J Rheumatol 2010; 37(12): 2578-86.
[42]
Scopaz KA, Piva SR, Wisniewski S, Fitzgerald GK. Relationships of fear, anxiety, and depression with physical function in patients with knee osteoarthritis. Arch Phys Med Rehabil 2009; 90(11): 1866-73.
[43]
Iverson GL. Screening for depression in systemic lupus erythematosus with the British Columbia Major Depression Inventory. Psychol Rep 2002; 90(3 Pt 2): 1091-6.
[45]
Frerichs RR, Aneshensel CS, Clark VA. Prevalence of depression in Los Angeles County. Am J Epidemiol 1981; 113(6): 691-9.
[46]
Harlow BL, Cohen LS, Otto MW, Spiegelman D, Cramer DW. Prevalence and predictors of depressive symptoms in older premenopausal women: The Harvard Study of Moods and Cycles. Arch Gen Psychiatry 1999; 56(5): 418-24.
[47]
Hammerlid E, Ahlner-Elmqvist M, Bjordal K, et al. A prospective multicentre study in Sweden and Norway of mental distress and psychiatric morbidity in head and neck cancer patients. Br J Cancer 1999; 80(5-6): 766-74.
[48]
Kugaya A, Akechi T, Okuyama T, et al. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 2000; 88(12): 2817-23.
[49]
Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 2000; 48(6): 579-84.
[50]
Macêdo E, Costallat L. Depression in systemic lupus erythematosus: gender differences in the performance of the Beck Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D), and Hospital Anxiety and Depression Scale (HADS). Lupus 2017; 27(2): 0961203317713142.
[51]
Mak A, Tang CS, Chan MF, Cheak AA, Ho RC. Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus. Clin Rheumatol 2011; 30(6): 795-803.
[52]
Tay SH, Cheung PP, Mak A. Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic lupus erythematosus. Lupus 2015; 24(13): 1392-9.
[53]
Yilmaz-Oner S, Oner C, Dogukan FM, et al. Anxiety and depression predict quality of life in Turkish patients with systemic lupus erythematosus. Clin Exp Rheumatol 2015; 33(3): 360-5.
[54]
Valtýsdóttir ST, Gudbjörnsson B, Lindqvist U, Hällgren R, Hetta J. Anxiety and depression in patients with primary Sjögren’s syndrome. J Rheumatol 2000; 27(1): 165-9.
[55]
Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 2012; 32(2): 323-30.
[56]
Buszewicz M, Rait G, Griffin M, et al. Self management of arthritis in primary care: randomised controlled trial. BMJ 2006; 333(7574): 879.
[57]
Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38(5): 898-903.
[58]
Murphy H, Dickens C, Creed F, Bernstein R. Depression, illness perception and coping in rheumatoid arthritis. J Psychosom Res 1999; 46(2): 155-64.
[59]
Mottram P, Wilson K, Copeland J. Validation of the Hamilton Depression Rating Scale and Montgommery and Asberg Rating Scales in terms of AGECAT depression cases. Int J Geriatr Psychiatry 2000; 15(12): 1113-9.
[60]
Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry 2000; 15(7): 644-9.
[61]
Bai R, Liu S, Zhao Y, et al. Depressive and anxiety disorders in systemic lupus erythematosus patients without major neuropsychiatric manifestations. J Immunol Res 2016; 2016: 2829018.
[62]
Xu J, Cheng YQ, Chen B, et al. Depression in systemic lupus erythematosus patients is associated with link-polymorphism but not methylation status of the 5HTT promoter region. Lupus 2013; 22(10): 1001-10.
[63]
Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010; 63(11): 1179-94.
[64]
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16(9): 606-13.
[65]
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092-7.
[66]
Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment 2011; 18(3): 263-83.
[67]
Schalet BD, Cook KF, Choi SW, Cella D. Establishing a common metric for self-reported anxiety: linking the MASQ, PANAS, and GAD-7 to PROMIS Anxiety. J Anxiety Disord 2014; 28(1): 88-96.
[68]
Choi SW, Schalet B, Cook KF, Cella D. Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression. Psychol Assess 2014; 26(2): 513-27.
[69]
Mitchell AJ, Yadegarfar M, Gill J, Stubbs B. Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. BJPsych Open 2016; 2(2): 127-38.
[70]
Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry 2015; 37(1): 67-75.
[71]
Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 2016; 39: 24-31.
[72]
Blalock SJ, DeVellis RF, Brown GK, Wallston KA. Validity of the Center for Epidemiological Studies Depression Scale in arthritis populations. Arthritis Rheum 1989; 32(8): 991-7.
[73]
Callahan LF, Kaplan MR, Pincus T. The Beck Depression Inventory, Center for Epidemiological Studies Depression Scale (CES-D), and General Well-Being Schedule depression subscale in rheumatoid arthritis. Criterion contamination of responses. Arthritis Care Res 1991; 4(1): 3-11.
[74]
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136-48.
[75]
Nery FG, Borba EF, Hatch JP, Soares JC, Bonfá E, Neto FL. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 2007; 48(1): 14-9.
[76]
Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61(6): 822-9.
[77]
Huang X, Magder LS, Petri M. Predictors of incident depression in systemic lupus erythematosus. J Rheumatol 2014; 41(9): 1823-33.
[78]
Waldheim E, Elkan AC, Pettersson S, et al. Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. Lupus 2013; 22(11): 1118-27.
[79]
Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004; 43(12): 1580-6.
[80]
Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005; 32(9): 1699-705.
[81]
van Exel E, Jacobs J, Korswagen LA, et al. Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus 2013; 22(14): 1462-9.
[82]
West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99(2): 153-63.
[83]
Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90(1): 54-62.
[84]
Jarpa E, Babul M, Calderón J, et al. Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 2011; 20(1): 58-66.
[85]
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81(10): 1361-7.
[86]
Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29(5)(Suppl. 68): S126-9.
[87]
Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012; 51(7): 1145-53.
[88]
Trupin L, Tonner MC, Yazdany J, et al. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. J Rheumatol 2008; 35(9): 1782-8.
[89]
Waheed A, Hameed K, Khan AM, Syed JA, Mirza AI. The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan. J Pak Med Assoc 2006; 56(5): 243-7.
[90]
Hanly JG, Su L, Urowitz MB, et al. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol 2015; 67(7): 1837-47.
[91]
Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S. Depression and systemic lupus erythematosus: a systematic review. Lupus 2013; 22(5): 409-16.
[92]
Utset TO, Chohan S, Booth SA, Laughlin JC, Kocherginsky M, Schmitz A. Correlates of formal work disability in an urban university systemic lupus erythematosus practice. J Rheumatol 2008; 35(6): 1046-52.
[93]
Huang H-C, Chou C-T, Lin K-C, Chao YF. The relationships between disability level, health-promoting lifestyle, and quality of life in outpatients with systemic lupus erythematosus. J Nurs Res 2007; 15(1): 21-32.
[94]
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 1121-3.
[95]
Burgos PI, Alarcón GS, McGwin G, et al. Disease Activity and Damage are not Associated with Increased Levels of Fatigue in Systemic Lupus Erythematosus Patients from LUMINA LXVII, a Multiethnic Cohort. Arthritis Rheum 2009; 61(9): 1179-86.
[96]
Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z. Performance of screening tests for cognitive impairment in systemic lupus erythematosus [in press]. J Rheumatol 2017; 44(11): 1583-9.
[97]
Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook RJ, Gladman DD. Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. J Rheumatol 2016; 43(6): 1057-62.
[98]
Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 1983; 5(4): 319-32.
[99]
Jolly M, Pickard AS, Mikolaitis RA, et al. Body image in patients with systemic lupus erythematosus. Int J Behav Med 2012; 19(2): 157-64.
[100]
McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus 2010; 19(14): 1640-7.
[101]
Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199-229.
[102]
Yirmiya R, Pollak Y, Morag M, et al. Illness, cytokines, and depression. Ann N Y Acad Sci 2000; 917: 478-87.
[103]
Yirmiya R, Weidenfeld J, Pollak Y, et al. Cytokines, “depression due to a general medical condition,” and antidepressant drugs. Adv Exp Med Biol 1999; 461: 283-316.
[104]
Sluzewska A. Indicators of immune activation in depressed patients. Adv Exp Med Biol 1999; 461: 59-73.
[105]
Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46.
[106]
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
[107]
Fonseca R, Bernardes M, Terroso G, de Sousa M, Figueiredo-Braga M. Silent Burdens in Disease: Fatigue and Depression in SLE. Autoimmune Dis 2014; 2014: 790724.
[108]
Braga J, Campar A. [Biological causes of depression in Systemic Lupus Erythematosus]. Acta Reumatol Port 2014; 39(3): 218-26.
[109]
Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005; 14(8): 571-5.
[110]
Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51(9): 1053-5.
[111]
Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41(12): 1357-66.
[112]
Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29(7): 1536-42.
[113]
Margaretten M, Yelin E, Imboden J, et al. Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. Arthritis Rheum 2009; 61(11): 1586-91.
[114]
Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12(1): 3-21.
[115]
Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276(4): 293-9.
[116]
Stansfeld SA, Head J, Marmot MG. Explaining social class differences in depression and well-being. Soc Psychiatry Psychiatr Epidemiol 1998; 33(1): 1-9.
[117]
Mackenbach JP, Kunst AE, Cavelaars AE, Groenhof F, Geurts JJ. Socioeconomic inequalities in morbidity and mortality in western Europe. Lancet 1997; 349(9066): 1655-9.
[118]
Criswell LA, Katz PP. Relationship of education level to treatment received for rheumatoid arthritis. J Rheumatol 1994; 21(11): 2026-33.
[119]
Turner RJ, Lloyd DA. The stress process and the social distribution of depression. J Health Soc Behav 1999; 40(4): 374-404.
[120]
Andreeva E, Magnusson Hanson LL, Westerlund H, Theorell T, Brenner MH. Depressive symptoms as a cause and effect of job loss in men and women: Evidence in the context of organisational downsizing from the Swedish Longitudinal Occupational Survey of Health. BMC Public Health 2015; 15(1): 1045.
[121]
Lim SS, Agan M, Drenkard CM. Impact of systemic lupus erythematosus organ damage on unemployment or disability from a population-based cohort. Arthritis Res Therapy 2012; 14(Suppl. 3): A13.
[122]
Mccormick N, Trupin L, Yelin EH, Katz PP. Socioeconomic Predictors of Incident Depression in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2018; 70(1): 104-13.
[123]
Katz P, Julian L, Tonner MC, et al. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64(4): 502-10.
[124]
Katz P, Yazdany J, Julian L, et al. Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63(10): 1357-64.
[125]
Baillet A, Zeboulon N, Gossec L, et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: Meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2010; 62(7): 984-92.
[126]
Conn VS, Hafdahl AR, Minor MA, Nielsen PJ. Physical activity interventions among adults with arthritis: Meta-analysis of outcomes. Semin Arthritis Rheum 2008; 37(5): 307-16.
[127]
Callahan LF, Mielenz T, Freburger J, et al. A randomized controlled trial of the people with arthritis can exercise program: Symptoms, function, physical activity, and psychosocial outcomes. Arthritis Rheum 2008; 59(1): 92-101.
[128]
Herring MP, Puetz TW, O’Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness: A systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172(2): 101-11.
[129]
Lee J, Chang RW, Ehrlich-Jones L, et al. Sedentary behavior and physical function: objective evidence from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2015; 67(3): 366-73.
[130]
Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23(8): 1407-17.
[131]
Sterling K, Gallop K, Swinburn P, et al. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Lupus 2014; 23(2): 124-32.
[132]
Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs 2006; 56(6): 617-35.
[133]
Teychenne M, Ball K, Salmon J. Physical activity, sedentary behavior and depression among disadvantaged women. Health Educ Res 2010; 25(4): 632-44.
[134]
Teychenne M, Ball K, Salmon J. Sedentary behavior and depression among adults: A review. Int J Behav Med 2010; 17(4): 246-54.
[135]
Katz PR, Trupin L, Barton J, et al. Obesity is a risk factor for depression in systemic lupus erythematosus. SLE 2014.
[136]
Macêdo EA, Appenzeller S, Costallat LT. Gender differences in systemic lupus erythematosus concerning anxiety, depression and quality of life. Lupus 2016; 25(12): 1315-27.
[137]
Torrente-Segarra V, Carbonell-Abelló J, Castro-Oreiro S, Manresa Domínguez JM. Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 2010; 28(6)(Suppl. 63): S22-6.
[138]
Lim LC, Lee TE, Boey ML. Psychiatric manifestation of systemic lupus erythematosus in Singapore. A cross-cultural comparison. Br J Psychiatry 1991; 159: 520-3.
[139]
Shortall E, Isenberg D, Newman SP. Factors associated with mood and mood disorders in SLE. Lupus 1995; 4(4): 272-9.
[140]
Fonseca R, Bernardes M, Terroso G, de Sousa M, Figueiredo-Braga M. Silent Burdens in Disease: Fatigue and Depression in SLE. Autoimmune Dis 2014; 2014: 790724.
Article Metrics
102
14
